Characterization of human adenovirus 35 and derivation of complex vectors

Virology Journal

Volumn 7, Issue , 2010, Pages

  McVey, Duncan ^a   Zuber, Mohammed ^a   EttyReddy, Damodar ^a   Reiter, Christopher D ^a   Brough, Douglas E ^a   Nabel, Gary J ^b   King, C Richter ^a,c   Gall, Jason G D ^a  

^a GENVEC INC   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; ADENOVIRUS 35; ARTICLE; DNA SYNTHESIS; GENE CONTROL; GENE DELETION; GENE VECTOR; GENETIC TRANSCRIPTION; NONHUMAN; OPEN READING FRAME; PROGENY; VIRUS CAPSID; VIRUS CHARACTERIZATION; VIRUS REPLICATION; GENE THERAPY; GENETICS; HUMAN; HUMAN ADENOVIRUS; METHODOLOGY; MICROBIAL VIABILITY; PHYSIOLOGY; VIRUS ASSEMBLY; VIRUS GENOME;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 35;

VIRUS PROTEIN;

ADENOVIRUS E1 PROTEINS; ADENOVIRUS E3 PROTEINS; ADENOVIRUS E4 PROTEINS; ADENOVIRUSES, HUMAN; GENE DELETION; GENE THERAPY; GENETIC VECTORS; GENOME, VIRAL; HUMANS; MICROBIAL VIABILITY; TRANSCRIPTION, GENETIC; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 77957915692     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-276     Document Type: Article

References (27)

1. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. R Vogels D Zuijdgeest R van Rijnsoever E Hartkoorn I Damen MP de Bethune S Kostense G Penders N Helmus W Koudstaal,, et al. Journal of virology 2003 77 8263 8271 10.1128/JVI.77.15.8263-8271.2003 12857895
2. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. P Abbink AA Lemckert BA Ewald DM Lynch M Denholtz S Smits L Holterman I Damen R Vogels AR Thorner,, et al. Journal of virology 2007 81 4654 4663 10.1128/JVI.02696-06 17329340
3. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. S Kostense W Koudstaal M Sprangers GJ Weverling G Penders N Helmus R Vogels M Bakker B Berkhout M Havenga J Goudsmit, AIDS (London, England) 2004 18 1213 1216 15166541
4. Development of adenovirus serotype 35 as a gene transfer vector. P Seshidhar Reddy S Ganesh MP Limbach T Brann A Pinkstaff M Kaloss M Kaleko S Connelly, Virology 2003 311 384 393 10.1016/S0042-6822(03)00161-2 12842627 (Pubitemid 36808779)
5. Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts. PR Flomenberg M Chen G Munk MS Horwitz, The Journal of infectious diseases 1987 155 1127 1134 3033089
6. Human adenovirus type 35: nucleotide sequence and vector development. W Gao PD Robbins A Gambotto, Gene therapy 2003 10 1941 1949 10.1038/sj.gt.3302097 14528318
7. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector. F Sakurai H Mizuguchi T Hayakawa, Gene therapy 2003 10 1041 1048 10.1038/sj.gt.3301959 12776162
8. Adenoviridae: The Viruses and Their Replication. AJ Berk, Fields Virology New York: Lippincott Williams & Wilkins, Knipe DM, Howley PM, Fifth 2007 2 2355 2394
9. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. M Havenga R Vogels D Zuijdgeest K Radosevic S Mueller M Sieuwerts F Weichold I Damen J Kaspers A Lemckert,, et al. The Journal of general virology 2006 87 2135 2143 10.1099/vir.0.81956-0 16847108
10. Promoter of the adenovirus polypeptide IX gene: similarity to E1B and inactivation by substitution of the simian virus 40 TATA element. LE Babiss LD Vales, Journal of virology 1991 65 598 605 1846185
11. Identification of adenovirus type 2 early region 1B proteins that share the same amino terminus as do the 495R and 155R proteins. JB Lewis CW Anderson, Journal of virology 1987 61 3879 3888 2960832
12. Expression of pIX gene induced by transgene promoter: possible cause of host immune response in first-generation adenoviral vectors. M Nakai K Komiya M Murata T Kimura M Kanaoka Y Kanegae I Saito, Human gene therapy 2007 18 925 936 10.1089/hum.2007.085 17907966
13. Packaging capacity and stability of human adenovirus type 5 vectors. AJ Bett L Prevec FL Graham, Journal of virology 1993 67 5911 5921 8371349
14. Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses. CF Basler MS Horwitz, Virology 1996 215 165 177 10.1006/viro.1996.0019 8560763
15. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. F Lemiale H Haddada GJ Nabel DE Brough CR King JG Gall, Vaccine 2007 25 2074 2084 10.1016/j.vaccine.2006.11.025 17250935
16. Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus. X Nan B Peng TW Hahn E Richardson A Lizonova I Kovesdi M Robert-Guroff, Gene therapy 2003 10 326 336 10.1038/sj.gt.3301903 12595891
17. Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. MM Hamilton GA Byrnes JG Gall DE Brough CR King LL Wei, Molecular vision 2008 14 2535 2546 19122827
18. Several E4 region functions influence mammary tumorigenesis by human adenovirus type 9. DL Thomas J Schaack H Vogel R Javier, Journal of virology 2001 75 557 568 10.1128/JVI.75.2.557-568.2001 11134268
19. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. RA Koup L Lamoreaux D Zarkowsky RT Bailer CR King JG Gall DE Brough BS Graham M Roederer, Journal of virology 2009 83 6318 6322 10.1128/JVI.00384-09 19339347
20. Infection of endothelium with E1(-)E4(+), but not E1(-)E4(-), adenovirus gene transfer vectors enhances leukocyte adhesion and migration by modulation of ICAM-1, VCAM-1, CD34, and chemokine expression. S Rafii S Dias S Meeus K Hattori R Ramachandran F Feuerback S Worgall NR Hackett RG Crystal, Circulation research 2001 88 903 910 10.1161/hh0901.089884 11348999
21. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. M Christ B Louis F Stoeckel A Dieterle L Grave D Dreyer J Kintz D Ali Hadji M Lusky M Mehtali, Human gene therapy 2000 11 415 427 10.1089/10430340050015888 10697116
22. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. DH Barouch MG Pau JH Custers W Koudstaal S Kostense MJ Havenga DM Truitt SM Sumida MG Kishko JC Arthur,, et al. J Immunol 2004 172 6290 6297 15128818
23. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. AA Lemckert SM Sumida L Holterman R Vogels DM Truitt DM Lynch A Nanda BA Ewald DA Gorgone MA Lifton,, et al. Journal of virology 2005 79 9694 9701 10.1128/JVI.79.15.9694-9701.2005 16014931
24. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. OJ Ophorst K Radosevic MJ Havenga MG Pau L Holterman B Berkhout J Goudsmit M Tsuji, Infection and immunity 2006 74 313 320 10.1128/IAI.74.1.313-320.2006 16368986
25. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. C Chartier E Degryse M Gantzer A Dieterle A Pavirani M Mehtali, Journal of virology 1996 70 4805 4810 8676512
26. Rapid construction of adenoviral vectors by lambda phage genetics. D McVey M Zuber D Ettyreddy DE Brough I Kovesdi, Journal of virology 2002 76 3670 3677 10.1128/JVI.76.8.3670-3677.2002 11907206
27. Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes. JG Gall A Lizonova D EttyReddy D McVey M Zuber I Kovesdi B Aughtman CR King DE Brough, Molecular biotechnology 2007 35 263 273 10.1007/BF02686012 17652790